- Trial phase
- Approved
- Time to market
- Already approved and marketed in the US (since March 2023) and EU (since August 2026). Japan regulatory filing planned for 2027 with potential launch in 2028.
- Why 4/10
- DAYBUE is already FDA-approved (March 2023) and EU-approved (August 2026) with no pending regulatory decision. The next catalyst is a Japan regulatory filing planned for 2027, which is more than 12 months out. As an approved, commercial-stage drug with no hard dated binary catalyst in the next ~12 months, the impact score is capped at 4 per the rubric.
DAYBUE is already approved and generating strong commercial revenue. The next catalyst for this specific drug is the planned Japan regulatory filing in 2027, which could support a 2028 launch, but no hard date is set. Watch quarterly DAYBUE sales growth trajectory and European launch uptake (Germany launched October 2026) as the key near-term value drivers for ACAD stock.
Price Chart
Executive Summary
DAYBUE (trofinetide) is Acadia Pharmaceuticals' approved treatment for Rett syndrome, a rare genetic neurological disorder. FDA-approved in March 2023 as the first and only treatment for the condition, it was also approved by the European Commission in August 2026. The drug generated strong Q3 2026 sales (up 39% YoY), leading Acadia to raise full-year guidance to $505-$520 million. A new powder formulation (DAYBUE STIX) launched in 2026, and patent protection was extended to 2041. A Phase 3 Japan study completed with positive results, supporting a planned 2027 regulatory filing. With no pending binary regulatory catalyst, DAYBUE is a mature commercial asset driving Acadia's revenue alongside NUPLAZID.
How It Works
Trofinetide is a synthetic version of a small protein fragment (GPE) that occurs naturally at the tip of IGF-1, a growth factor important for brain development. In Rett syndrome, IGF-1 levels in the brain are lower than normal, which is thought to impair nerve cell function. Trofinetide is designed to compensate for this deficiency by supporting neuronal connections and reducing inflammation in the brain. It is taken by mouth as a liquid or powder solution.
Trial Status
DAYBUE was approved by the FDA in March 2023 based on the Phase 3 LAVENDER study (NCT04181723), a 12-week randomized, double-blind, placebo-controlled trial in patients aged 5-20. The Phase 3 Japan study has been completed with results consistent with LAVENDER, supporting a planned regulatory filing in 2027. Real-world effectiveness studies continue to publish positive data.
The Two-Sided Case
Upcoming Catalysts
- Japan regulatory filing for trofinetide planned for 2027 (potential launch 2028)
- European commercial launch rollout across additional EU countries following Germany launch in October 2026
- Quarterly DAYBUE sales reports as key commercial performance indicators
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ACADIA PHARMACEUTICALS INC 8-K ACAD ·Originating report